Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003 Dec 18;40(6):1087-93. PubMed Abstract, View on AlzSWAN

REAGENTS/MATERIAL:

All mice in the study were F1 progeny derived from a single cross between the APPSwe/Ind transgenic mice J20 line (gift of Lennart Mucke) and NEP or IDE transgenic mice (The Jackson Laboratory).

Serial sections from each animal were stained with each of the following antibodies: our pAb DW14 (1:2500) for human Ab detection (Walsh et al., 2002a); mAb GFAP (1:500; Sigma, St. Louis, MO) for detection of reactive astrocytes; mAb APP 8E5 (1:10,000; gift from Elan Pharmaceuticals) reactive for full-length human APP, for detection of dystrophic neurites; and mAb anti-CD45 (1:5000; Serotec Ltd, Oxford, UK), for detection of microglia.

Antibodies used for Western blots included IDE-1 (Vekrellis et al., 2000), APP 8E5, and C8 (reactive with the carboxy terminus of APP), and the following anti-NEP antibodies: 56C6, CD10(C-17), CD10(N-14), CD10(H-321) (Santa Cruz Biotechnology, Inc.), and NEP11-A (Alpha Diagnostic Intl.).